Stuttgart - Delayed Quote • EUR ChromaDex Corp (OCD1.SG) Follow 3.1600 -0.0200 (-0.63%) As of April 25 at 4:05 PM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for OCD1.SG 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: OCD1.SG View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now? Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock? ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program ChromaDex Full Year 2023 Earnings: EPS Beats Expectations ChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDA ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript Q4 2023 Chromadex Corp Earnings Call ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results Insiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the company
